This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Tascilar, M. Articles by Goggins, M. Search for Related Content PubMed PubMed Citation Articles by Tascilar, M. Articles by Goggins, M. Related Collections Commentary

The SMAD4 Protein and Prognosis of Pancreatic Ductal Adenocarcinoma

Departments of Pathology [M. T., C. R., R. E. W., S. E. K., R. H. H., M. G.], Surgery [T. S., J. L. C., C. J. Y.], Oncology [R. A. A., S. E. K., R. H. H., M. G.], and Medicine [M. G.], The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205; Department of Epidemiology, The Johns Hopkins School of Public Health, Baltimore, Maryland 21205 [H. G. S.]; Department of Pathology, Academic Medical Center, Amsterdam, the Netherlands [M. T., J. O.]; and Department of Pathology, Karmonos Cancer Institute, Harper Hospital, Detroit Medical Center, Wayne State University School of Medicine, Detroit, Michigan [V. A.]

Purpose: SMAD4 (also called Dpc4) is a tumor suppressor in the TGF-ß signaling pathway that is genetically inactivated in 55% of all pancreatic adenocarcinomas. We investigated whether prognosis after surgical resection for invasive pancreatic adenocarcinoma is influenced by SMAD4 status.

Experimental Design: Using immunohistochemistry, we characterized the SMAD4 protein status of 249 pancreatic adenocarcinomas resected from patients who underwent pancreaticoduodenectomy (Whipple resection) at The Johns Hopkins Hospital, Baltimore, MD, between 1990 and 1997. The SMAD4 gene status of 56 of 249 (22%) pancreatic carcinomas was also determined. A multivariate Cox proportional hazards model assessed the relative risk of mortality associated with SMAD4 status, adjusting for known prognostic variables.

Results: Patients with pancreatic adenocarcinomas with SMAD4 protein expression had significantly longer survival (unadjusted median survival was 19.2 months as compared with 14.7 months in patients with pancreatic cancers lacking SMAD4 protein expression; P = 0.03). This SMAD4 survival benefit persisted after adjustment for prognostic factors including tumor size, margins, lymph node status, pathological stage, blood loss, and use of adjuvant chemoradiotherapy. The relative hazard of mortality for cancers lacking SMAD4 after adjusting for other prognostic factors was 1.36 (95% confidence interval, 1.01–1.83; P = 0.04).

Conclusion: Patients undergoing Whipple resection for pancreatic adenocarcinoma survive longer if their cancers express SMAD4.

Commentary

SMAD4/DPC4 and Pancreatic Cancer Survival : Commentary re: M. Tascilar et al., The SMAD4 Protein and Prognosis of Pancreatic Ductal Adenocarcinoma. Clin. Cancer Res., 7: 4115–4121, 2001.

Fang Liu
Clin. Cancer Res. 2001 7: 3853-3856. [Full Text] [PDF]

This article has been cited by other articles:

				J. R. Infante, H. Matsubayashi, N. Sato, J. Tonascia, A. P. Klein, T. A. Riall, C. Yeo, C. Iacobuzio-Donahue, and M. Goggins Peritumoral Fibroblast SPARC Expression and Patient Outcome With Resectable Pancreatic Adenocarcinoma J. Clin. Oncol., January 20, 2007; 25(3): 319 - 325. [Abstract] [Full Text] [PDF]

				N. Bardeesy, K.-h. Cheng, J. H. Berger, G. C. Chu, J. Pahler, P. Olson, A. F. Hezel, J. Horner, G. Y. Lauwers, D. Hanahan, et al. Smad4 is dispensable for normal pancreas development yet critical in progression and tumor biology of pancreas cancer. Genes & Dev., November 15, 2006; 20(22): 3130 - 3146. [Abstract] [Full Text] [PDF]

				H. Wang, H. Han, and D. D. Von Hoff Identification of an Agent Selectively Targeting DPC4 (Deleted in Pancreatic Cancer Locus 4)-Deficient Pancreatic Cancer Cells Cancer Res., October 1, 2006; 66(19): 9722 - 9730. [Abstract] [Full Text] [PDF]

				F Bergmann, S Aulmann, M N Wente, R Penzel, I Esposito, J Kleeff, H Friess, and P Schirmacher Molecular characterisation of pancreatic ductal adenocarcinoma in patients under 40 J. Clin. Pathol., June 1, 2006; 59(6): 580 - 584. [Abstract] [Full Text] [PDF]

				A. F. Hezel, A. C. Kimmelman, B. Z. Stanger, N. Bardeesy, and R. A. DePinho Genetics and biology of pancreatic ductal adenocarcinoma. Genes & Dev., May 15, 2006; 20(10): 1218 - 1249. [Abstract] [Full Text] [PDF]

				H. Matsubayashi, M. Canto, N. Sato, A. Klein, T. Abe, K. Yamashita, C. J. Yeo, A. Kalloo, R. Hruban, and M. Goggins DNA Methylation Alterations in the Pancreatic Juice of Patients with Suspected Pancreatic Disease Cancer Res., January 15, 2006; 66(2): 1208 - 1217. [Abstract] [Full Text] [PDF]

				M. Goggins Molecular Markers of Early Pancreatic Cancer J. Clin. Oncol., July 10, 2005; 23(20): 4524 - 4531. [Abstract] [Full Text] [PDF]

				M. Wan, J. Huang, N. C. Jhala, E. M. Tytler, L. Yang, S. M. Vickers, Y. Tang, C. Lu, N. Wang, and X. Cao SCF{beta}-TrCP1 Controls Smad4 Protein Stability in Pancreatic Cancer Cells Am. J. Pathol., May 1, 2005; 166(5): 1379 - 1392. [Abstract] [Full Text] [PDF]

				D. Vimalachandran, W. Greenhalf, C. Thompson, J. Luttges, W. Prime, F. Campbell, A. Dodson, R. Watson, T. Crnogorac-Jurcevic, N. Lemoine, et al. High Nuclear S100A6 (Calcyclin) Is Significantly Associated with Poor Survival in Pancreatic Cancer Patients Cancer Res., April 15, 2005; 65(8): 3218 - 3225. [Abstract] [Full Text] [PDF]

				M. Abdelrahim, R. Smith III, R. Burghardt, and S. Safe Role of Sp Proteins in Regulation of Vascular Endothelial Growth Factor Expression and Proliferation of Pancreatic Cancer Cells Cancer Res., September 15, 2004; 64(18): 6740 - 6749. [Abstract] [Full Text] [PDF]

				H. G. Skinner, D. S. Michaud, E. L. Giovannucci, E. B. Rimm, M. J. Stampfer, W. C. Willett, G. A. Colditz, and C. S. Fuchs A Prospective Study of Folate Intake and the Risk of Pancreatic Cancer in Men and Women Am. J. Epidemiol., August 1, 2004; 160(3): 248 - 258. [Abstract] [Full Text] [PDF]

				G. Subramanian, R. E. Schwarz, L. Higgins, G. McEnroe, S. Chakravarty, S. Dugar, and M. Reiss Targeting Endogenous Transforming Growth Factor {beta} Receptor Signaling in SMAD4-Deficient Human Pancreatic Carcinoma Cells Inhibits Their Invasive Phenotype1 Cancer Res., August 1, 2004; 64(15): 5200 - 5211. [Abstract] [Full Text] [PDF]

				H. Takahashi, T. Oda, T. Hasebe, Y. Aoyagi, T. Kinoshita, M. Konishi, T. Nakagohri, K. Inoue, S. Takahashi, H. Kawahira, et al. Biologically Different Subgroups of Invasive Ductal Carcinoma of the Pancreas: Dpc4 Status According to the Ratio of Intraductal Carcinoma Components Clin. Cancer Res., June 1, 2004; 10(11): 3772 - 3779. [Abstract] [Full Text] [PDF]

				Y. H. Kim, H. S. Lee, H.-J. Lee, K. Hur, W. H. Kim, Y.-J. Bang, S.-J. Kim, K. U. Lee, K. J. Choe, and H.-K. Yang Prognostic significance of the expression of Smad4 and Smad7 in human gastric carcinomas Ann. Onc., April 1, 2004; 15(4): 574 - 580. [Abstract] [Full Text] [PDF]

				A. V. Biankin, A. L. Morey, C.-S. Lee, J. G. Kench, S. A. Biankin, H. C. Hook, D. R. Head, T. B. Hugh, R. L. Sutherland, and S. M. Henshall DPC4/Smad4 Expression and Outcome in Pancreatic Ductal Adenocarcinoma J. Clin. Oncol., December 1, 2002; 20(23): 4531 - 4542. [Abstract] [Full Text] [PDF]